Breast cancer research : BCR · 2026
Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buyukkuscu Asli, Isleyen Zehra Sucuoglu, Ekinci Omer Burak, Atasever Tugay, Akkaya Kubra, Aydin Okan, Kulduk Gamze, Celik Emir, Erturk Kayhan, Atci M Mustafa
Аннотация
BACKGROUND: Anthracycline-free neoadjuvant chemotherapy combined with dual HER2 blockade represents an alternative to anthracycline-containing regimens in early-stage HER2-positive breast cancer; however, real-world evidence remains limited.
METHODS: We retrospectively analyzed 162 patients with stage I-III HER2-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab between 2022 and 2025. Patients received anthracycline-free (TCHP/TCH; n = 51) or anthracycline-containing (AC-THP/AC-TH; n = 111) chemotherapy. The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). Secondary endpoints included treatment-related toxicity and cardiac safety.
RESULTS: The overall pCR rate was 56.8%. pCR was achieved in 64.7% of patients in the TCHP/TCH group and 53.2% in the AC-THP/AC-TH group (p = 0.168). In multivariable analysis, age > 65 years was associated with a lower probability of pCR (OR 0.08; 95% CI, 0.01-0.57), while hormone receptor-negative status was associated with higher pCR rates (OR 2.21; 95% CI, 1.02-4.76). Grade 3-4 hematologic and gastrointestinal toxicities differed between regimens. Cardiac toxicity was rare and similar between groups.
CONCLUSIONS: In a real-world setting, anthracycline-free neoadjuvant chemotherapy with dual HER2 blockade achieved pCR rates comparable to anthracycline-containing regimens with acceptable toxicity and preserved cardiac safety, suggesting that it may be a reasonable treatment option for selected patients.
METHODS: We retrospectively analyzed 162 patients with stage I-III HER2-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab between 2022 and 2025. Patients received anthracycline-free (TCHP/TCH; n = 51) or anthracycline-containing (AC-THP/AC-TH; n = 111) chemotherapy. The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). Secondary endpoints included treatment-related toxicity and cardiac safety.
RESULTS: The overall pCR rate was 56.8%. pCR was achieved in 64.7% of patients in the TCHP/TCH group and 53.2% in the AC-THP/AC-TH group (p = 0.168). In multivariable analysis, age > 65 years was associated with a lower probability of pCR (OR 0.08; 95% CI, 0.01-0.57), while hormone receptor-negative status was associated with higher pCR rates (OR 2.21; 95% CI, 1.02-4.76). Grade 3-4 hematologic and gastrointestinal toxicities differed between regimens. Cardiac toxicity was rare and similar between groups.
CONCLUSIONS: In a real-world setting, anthracycline-free neoadjuvant chemotherapy with dual HER2 blockade achieved pCR rates comparable to anthracycline-containing regimens with acceptable toxicity and preserved cardiac safety, suggesting that it may be a reasonable treatment option for selected patients.